MultiCell’s epitope-based T-cell immunotherapy (ETI) technology platform involves the delivery of specific epitopes to the immune system to generate a desired immune response.  The ETI technology has the ability to control the magnitude and profile of the immune response, namely immune suppression in the case of an autoimmune disease or immune stimulation in the case of infectious disease or cancer. The uniqueness of MultiCell’s ETI technology is related to the use of a delivery vehicle, namely the use of immunoglobulins, that are engineered to bear specific disease-associated epitope peptides or fusion molecules to greatly improve the pharmacokinetics of delivered epitopes to antigen presenting cells, thereby helping to better regulate the profile of the immune response. The ETI technology is engineered to selectively affect the T-cell response to disease-associated molecules by specifically targeting the auto-aggressive T-lymphocytes, while leaving the rest of the immune system functional. ETI is an in vivo technology that is applicable to all patient groups, and does not require patient-customized processing.  In addition, ETI does not involve viral or cell-based vectors, and thus does not elicit the untoward immune responses associated with these vectors.  T-cells are fundamental to all immune responses, and are critical in fighting diseases such as cancer and viruses. A properly functioning immune system responds with various methods to invasion by bacteria, viruses, and other micro-organisms, and provides a highly effective means of eliminating those cells within the body that might have become injured or defective (such as cancer cells), or that are not recognized as being a normal part of the body (such as a transplanted organ).